Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) target price raised to $9.25, reported today by Zacks Investment Research
- Updated: October 4, 2016
Yesterday Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded -1.62% lower at $7.91. The company’s 50-day moving average is $8.35 and its 200-day moving average is $8.46. The last stock close price is down -6.53% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 714,705 shares of the stock were exchanged, down from an average trading volume of 1,436,540
Indicating a possible upside of 0.17%, Zacks Investment Research increased the stock price target of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $9.25
Previously on Friday September 23, 2016, Chardan Capital reported about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) raised the target price from $4.00 to $5.00. At the time, this indicated a possible downside of -0.41%.
See Chart Below
Achillion Pharmaceuticals, Inc. has a 52 week low of $5.57 and a 52 week high of $10.95 with a P/E ratio of 161.43 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 5 analysts have released a research note on ACHN. The one year target is $9.40 with two analysts rating the company a strong buy, one equity analyst rating the company a buy, three equity analysts rating the company a hold, one equity analyst rating the company a underperform, and lastly zero equity analysts rating the company a sell.
Brief Synopsis About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.